

Yan Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8864400/publications.pdf>

Version: 2024-02-01

13
papers

715
citations

1040056

9
h-index

1199594

12
g-index

13
all docs

13
docs citations

13
times ranked

1209
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypoxia regulates Hippo signalling through the SIAH2 ubiquitin E3 ligase. <i>Nature Cell Biology</i> , 2015, 17, 95-103.	10.3	199
2	ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis. <i>Journal of Clinical Investigation</i> , 2018, 128, 1937-1955.	8.2	126
3	HIF2-Induced Long Noncoding RNA RAB11B-AS1 Promotes Hypoxia-Mediated Angiogenesis and Breast Cancer Metastasis. <i>Cancer Research</i> , 2020, 80, 964-975.	0.9	123
4	Methylation of hypoxia-inducible factor (HIF)-1 β by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration. <i>Nucleic Acids Research</i> , 2018, 46, 6576-6591.	14.5	90
5	Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 195-206.	5.4	74
6	Ci antagonizes Hippo signaling in the somatic cells of the ovary to drive germline stem cell differentiation. <i>Cell Research</i> , 2015, 25, 1152-1170.	12.0	30
7	Chimeric RNA ASTN2-PAPPAAs aggravates tumor progression and metastasis in human esophageal cancer. <i>Cancer Letters</i> , 2021, 501, 1-11.	7.2	15
8	USP5 promotes breast cancer cell proliferation and metastasis by stabilizing HIF2 β . <i>Journal of Cellular Physiology</i> , 2022, 237, 2211-2219.	4.1	13
9	Romance of the three kingdoms in hypoxia: HIFs, epigenetic regulators, and chromatin reprogramming. <i>Cancer Letters</i> , 2020, 495, 211-223.	7.2	12
10	Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple-negative breast cancer by stabilizing Snail1. <i>Journal of Cellular Physiology</i> , 2022, 237, 2992-3000.	4.1	11
11	The multifaceted functions of RNA helicases in the adaptive cellular response to hypoxia: From mechanisms to therapeutics. , 2021, 221, 107783.		8
12	ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells. <i>Science Advances</i> , 2022, 8, .	10.3	8
13	ZMYND8 is a primary HIF coactivator that mediates breast cancer progression. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1479619.	0.7	6